TDC
ARGS

Thompson Davis & Co’s Argos Therapeutics, Inc. ARGS Stock Holding History

Thompson Davis & Co’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-25
Closed -$5K – 1378
2014
Q4 		$5K Hold
25
– – 0.01% 968
2014
Q3 		$5K Hold
25
– – 0.01% 922
2014
Q2 		$4K Hold
25
– – 0.01% 669
2014
Q1 		$5K Buy
+25
New +$5K 0.01% 661

Other funds holding ARGS

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Caisse de Depot et Placement du Quebec (CDPQ)
Caisse de Depot et Placement du Quebec (CDPQ) Montreal, Quebec, Canada $62.4B AUM 23.7% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.54% 1-Year Est. Return
Ohio Public Employees Retirement System (OPERS)
Ohio Public Employees Retirement System (OPERS) Columbus, Ohio $30.9B AUM 29.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thompson Davis & Co's ARGS Position: Q1 2015 in Review

Thompson Davis & Co sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2015, closing a stake of 25 shares — an estimated $5K sold.

Thompson Davis & Co first reported a position in ARGS in Q1 2014 and held it in 4 quarters. The position peaked at $5K in Q4 2014. 25 funds tracked by Wall St. Rank hold ARGS as of Q1 2015.

  • Thompson Davis & Co reported no remaining Argos Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Thompson Davis & Co sold 25 Argos Therapeutics, Inc. shares in Q1 2015, an estimated $5K.
  • Thompson Davis & Co first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
  • Thompson Davis & Co's Argos Therapeutics, Inc. position peaked at $5K in Q4 2014.
  • 25 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2015.

Based on Thompson Davis & Co's 13F filing for Q1 2015, filed 28 Apr 2015.